These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37016126)

  • 1. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
    Bendell J; LoRusso P; Overman M; Noonan AM; Kim DW; Strickler JH; Kim SW; Clarke S; George TJ; Grimison PS; Barve M; Amin M; Desai J; Wise-Draper T; Eck S; Jiang Y; Khan AA; Wu Y; Martin P; Cooper ZA; Elgeioushi N; Mueller N; Kumar R; Patel SP
    Cancer Immunol Immunother; 2023 Jul; 72(7):2443-2458. PubMed ID: 37016126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
    Kim DW; Kim SW; Camidge DR; Shu CA; Marrone KA; Le X; Blakely CM; Park K; Chang GC; Patel SP; Kar G; Cooper ZA; Samadani R; Pluta M; Kumar R; Ramalingam S
    J Thorac Oncol; 2023 May; 18(5):650-656. PubMed ID: 36641093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
    Herbst RS; Majem M; Barlesi F; Carcereny E; Chu Q; Monnet I; Sanchez-Hernandez A; Dakhil S; Camidge DR; Winzer L; Soo-Hoo Y; Cooper ZA; Kumar R; Bothos J; Aggarwal C; Martinez-Marti A
    J Clin Oncol; 2022 Oct; 40(29):3383-3393. PubMed ID: 35452273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
    Patel SP; Alonso-Gordoa T; Banerjee S; Wang D; Naidoo J; Standifer NE; Palmer DC; Cheng LY; Kourtesis P; Ascierto ML; Das M; Diamond JR; Hellmann MD; Carneiro BA
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38309722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
    Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
    Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Besse B; Pons-Tostivint E; Park K; Hartl S; Forde PM; Hochmair MJ; Awad MM; Thomas M; Goss G; Wheatley-Price P; Shepherd FA; Florescu M; Cheema P; Chu QSC; Kim SW; Morgensztern D; Johnson ML; Cousin S; Kim DW; Moskovitz MT; Vicente D; Aronson B; Hobson R; Ambrose HJ; Khosla S; Reddy A; Russell DL; Keddar MR; Conway JP; Barrett JC; Dean E; Kumar R; Dressman M; Jewsbury PJ; Iyer S; Barry ST; Cosaert J; Heymach JV
    Nat Med; 2024 Mar; 30(3):716-729. PubMed ID: 38351187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
    Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
    Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
    Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.
    Barlesi F; Cho BC; Goldberg SB; Yoh K; Zimmer Gelatti AC; Mann H; Gopinathan A; Bielecka ZF; Newton M; Aggarwal C
    Future Oncol; 2024 Jul; ():1-11. PubMed ID: 39023287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC
    JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
    Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
    Mirza MR; Tandaric L; Henriksen JR; Mäenpää J; Christensen RD; Waldstrøm M; Lindemann K; Roed H; Auranen A; Akslen LA; Thomsen LCV; Lindberg SN; Madsen K; Bjørge L
    Gynecol Oncol; 2024 Jun; 188():103-110. PubMed ID: 38943691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
    Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
    Falchook GS; Reeves J; Gandhi S; Spigel DR; Arrowsmith E; George DJ; Karlix J; Pouliot G; Hattersley MM; Gangl ET; James GD; Thompson J; Russell DL; Patel B; Kumar R; Lim E
    Cancer Immunol Immunother; 2024 Mar; 73(4):72. PubMed ID: 38430405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
    Cascone T; Kar G; Spicer JD; García-Campelo R; Weder W; Daniel DB; Spigel DR; Hussein M; Mazieres J; Oliveira J; Yau EH; Spira AI; Anagnostou V; Mager R; Hamid O; Cheng LY; Zheng Y; Blando J; Tan TH; Surace M; Rodriguez-Canales J; Gopalakrishnan V; Sellman BR; Grenga I; Soo-Hoo Y; Kumar R; McGrath L; Forde PM
    Cancer Discov; 2023 Nov; 13(11):2394-2411. PubMed ID: 37707791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.